Replies to post #110962 on NorthWest Biotherapeutics Inc (NWBO)

[chinatown1980]

You have done a remarkable job promoting the company and stock over the years. I know you will undoubtedly continue to do so, even if the stock is reduced by another 50% from current levels, undergoes its 3rd reverse split, and is decimated once again through toxic dilution. Your support will be unwaivering through everything, of this I am certain. I don't believe your efforts would even be stifled by bankruptcy, an unfavorable outcome of the SEC inquiry, or phase 3 trial failure.

Yes, I do find the SEC inquiry intriguing and very concerning as a shareholder. I imagine my feelings may be similar to how Enron shareholders likely felt regarding the SEC inquiry in 2001 into corporate governance and related party transactions of the CFO. Events which ultimately led to a formal investigation and the final chapter of existence.

[chinatown1980]

you spend none of your time here sharing any of the DD you find with us.

That is true, most of the fruits of my DD lately have not been positive for the company, the management, or the science.

Since this is the second time recently you have criticized my lack of DD, maybe I will discuss something. I thought of posting it a week ago when I first watched the video, but decided against it. Anyway in the video posted on Medscape entitled "Management of Glioblastoma: Where Have We Been and Where Are We Going?" Dr. Prins and Dr. Martin van deb Bent have an interesting discussion about the various recent trials for GBM.

Dr. Bent has some very interesting takeaways from the failed CLDX Rindo trial that I found very interesting. Some of his overall comments were similar to what we heard in December from Dr. Liau. Like early phase trials and patient selection bias for example, and how early positive results from small samples didn't always lead to a favorable outcome in the controlled trial setting. But what I found most interesting were his comments regarding the failed CLDX Rindo trial and how the trial protocol and patient characters led to "everyone living longer" in the trial.

I'm curious if you/flipper watched the video? What parallels (if any) do you see between the ACT IV trial and the L phase 3? Which of Dr. Bent's comments and concerns do you think may be applicable to the L phase 3 trial? Why do you suppose Dr. Prins didn't make more mention of vaccines playing a significant role in the future treatment landscape as a single agent? Why do you suppose there seems to be a marked shift by the doctors heavily involved in the vaccine research at UCLA toward combination trials offering the best avenue for GBM treatment exploration going forward?